JW JoongWai Enhances Management Application for Hemophilia A Treatment 'Hemlibra'

JW Pharmaceutical's 'Hemlibra' Application (Photo by JW Pharmaceutical)

[Asia Economy Reporter Lee Chun-hee] JW Pharmaceutical announced on the 27th that it has updated the functions of the ‘Hemlibra’ application (app) to enhance the provision of medication information for hemophilia patients.

The Hemlibra app is designed to support disease education and medication guidance for patients prescribed Hemlibra, a prophylactic treatment for hemophilia A. It was developed as part of JW Pharmaceutical’s ‘Bravo Campaign,’ which aims to raise social awareness of rare diseases and help patients overcome their conditions.

Through the Hemlibra app, patients can check disease information, medication-related product details, and set up medication and injection diaries. The updated app allows users to easily view medication intervals and injection site information through alerts at a glance.

Until now, all hemophilia A treatments required intravenous injections (IV) two to three times a week, but Hemlibra is characterized by subcutaneous injections (SC) administered from once a week up to once every four weeks. The app notifies users of previous subcutaneous injection sites three times (one day before medication, one hour before, and one hour after) so that injections can be administered at different sites as recommended in the medication guide. Additionally, a ‘Write Injection Diary’ button has been added to the home screen, making it easy to record injection diaries after medication.

A JW Pharmaceutical official stated, “We revamped the Hemlibra app to help prevent adverse reactions such as skin discoloration that can occur when injecting into the same site,” and added, “We will continue to lead efforts to improve the treatment environment for patients with rare diseases such as hemophilia.”

This content was produced with the assistance of AI translation services.